Newsfeeds Archive - Spark Newswire

1 minute read

Ascendis Pharma To Present New Data And Updated Results From Phase 1/2 IL-Believe Trial At ASCO 2024

June 3, 4:05 PM

- 40% of efficacy-evaluable patients (2 out of 5) in the initial cohort of patients with anti-PD-1 refractory melanoma treated with TransCon IL-2 β/γ in combination with TransCon TLR7/8 Agonist exhibited

ASND

2 minute read

(ASND) – Analyzing Ascendis Pharma’s Short Interest

By Benzinga Insights

May 28, 10:00 AM

Ascendis Pharma’s (NYSE:ASND) short percent of float has fallen 7.55% since its last report. The company recently reported…

ASND

2 minute read

FDA Pushes Review Date For Ascendis Pharma’s Hormone Disorder Candidate By Three Months

By Vandana Singh

May 15, 11:57 AM

Ascendis Pharma announces FDA's extension of the review date for TransCon PTH for adults with hypoparathyroidism to August 14, 2024. TransCon PTH aims to address low calcium levels due to hypoparathyroidism.

ASND

1 minute read

Ascendis Pharma A/S Clinical And Quality-Of-Life Data For TransCon PTH-Treated Adults With Chronic Hypoparathyroidism To Be Presented At ECE 2024

By Benzinga Newsdesk

May 9, 9:17 AM

Ascendis Pharma A/S (NASDAQ:ASND) today announced that new TransCon PTH (palopegteriparatide) data supporting clinical and quality-of-life benefits in adult patients with chronic hypoparathyroidism will be presented at

ASND

2 minute read

Looking Into Ascendis Pharma’s Recent Short Interest

By Benzinga Insights

April 26, 11:30 AM

Ascendis Pharma’s (NYSE:ASND) short percent of float has risen 13.75% since its last report. The company recently reported…

ASND

2 minute read

How Is The Market Feeling About Ascendis Pharma?

By Benzinga Insights

February 13, 9:15 AM

Ascendis Pharma’s (NYSE:ASND) short percent of float has fallen 6.4% since its last report. The company recently reported…

ASND

11 minute read

Earnings

Earnings Scheduled For February 7, 2024

By Benzinga Insights

February 7, 6:13 AM

Companies Reporting Before The Bell • Madison Square Garden (NYSE:MSGE) is expected to report quarterly loss at $0.80 per share on revenue of $301.83 million.

ACLS

1 minute read

Earnings

Ascendis Pharma’s Earnings: A Preview

By Benzinga Insights

February 6, 1:01 PM

Ascendis Pharma (NASDAQ:ASND) is set to give its latest quarterly earnings report on Wednesday, 2024-02-07. Here’s what investors…

ASND

2 minute read

Er-Kim Announces Exclusive Distribution Agreement With Ascendis Pharma A/S To Commercialize 3 Endocrinology Disease Treatments Across Central & Eastern Europe And Turkey

By Benzinga Newsdesk

January 8, 11:58 PM

Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies, today announced it has entered into an exclusive distribution agreement with Danish Company Ascendis Pharma A/S

ASND

4 minute read

Ascendis Pharma Introduces Vision 2030; Preliminary Unaudited December 31, 2023 Cash, Cash Equivalents, And Marketable Securities Of ~€400M; Full Year 2024 SKYTROFA Revenue Expected To Be €320M-€340M

By Benzinga Newsdesk

January 7, 9:16 PM

Strategic roadmap to achieve blockbuster status for multiple products and expandthe Company's engine for future innovation COPENHAGEN, Denmark, Jan. 07, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND)

ASND